Identification of PPARgamma Partial Agonists of Natural Origin (I): Development of a Virtual Screening Procedure and In Vitro Validation

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Guasch, Laura ^a   Sala, Esther ^a   Castell Auví, Anna ^a   Cedó, Lidia ^a   Liedl, Klaus R ^b   Wolber, Gerhard ^c   Muehlbacher, Markus ^b,d   Mulero, Miquel ^a   Pinent, Montserrat ^a   Ardévol, Anna ^a   Valls, Cristina ^a   Pujadas, Gerard ^a,e   Garcia Vallvé, Santiago ^a,e  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e TECNIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; UNCLASSIFIED DRUG; ZINC 00083676; ZINC 00201868; ZINC 00914339; ZINC 02118312; ZINC 02128851; ZINC 02156886; ZINC 03846929; ZINC 04040746; ZINC 04085288; ZINC 08879322;

ARTICLE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; GLUCOSE TRANSPORT; IN VITRO STUDY; LIGAND BINDING; MOLECULAR DOCKING; PROCESS DEVELOPMENT; TRANSACTIVATION; VALIDATION STUDY; VIRTUAL SCREENING; WORKFLOW;

3T3-L1 CELLS; ANIMALS; BIOLOGICAL AGENTS; DATABASES, PHARMACEUTICAL; DRUG EVALUATION, PRECLINICAL; DRUG PARTIAL AGONISM; HUMANS; HYPOGLYCEMIC AGENTS; MICE; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; PPAR GAMMA; PROTEIN CONFORMATION; REPRODUCIBILITY OF RESULTS; USER-COMPUTER INTERFACE;

EID: 84870726015     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050816     Document Type: Article

References (46)

1. Francis GA, Fayard E, Picard F, Auwerx J, (2003) Nuclear receptors and the control of metabolism. Annu Rev Physiol 65: 261-311.
2. Garcia-Vallvé S, Palau J, (1998) Nuclear receptors, nuclear-receptor factors, and nuclear-receptor-like orphans form a large paralog cluster in Homo sapiens. Mol Biol Evol 15: 665-682.
3. Berger J, Moller DE, (2002) The mechanisms of action of PPARs. Annu Rev Med 53: 409-435.
4. Shearer BG, Billin AN, (2007) The next generation of PPAR drugs: do we have the tools to find them? Biochim Biophys Acta 1771: 1082-1093.
5. Willson TM, Brown PJ, Sternbach DD, Henke BR, (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem 43: 527-550.
6. Feldman PL, Lambert MH, Henke BR, (2008) PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors? Curr Top Med Chem 8: 728-749.
7. Pourcet B, Fruchart J-C, Staels B, Glineur C, (2006) Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis. Expert Opin Emerg Drugs 11: 379-401.
8. Jones D, (2010) Potential remains for PPAR-targeted drugs. Nat Rev Drug Discov 9: 668-669.
9. Guasch L, Sala E, Valls C, Blay M, Mulero M, et al. (2011) Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity. J Comput Aided Mol Des 25: 717-728.
10. Zoete V, Grosdidier A, Michielin O, (2007) Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta 1771: 915-925.
11. Farce A, Renault N, Chavatte P, (2009) Structural insight into PPARgamma ligands binding. Curr Med Chem 16: 1768-1789.
12. Bruning JB, Chalmers MJ, Prasad S, Busby SA, Kamenecka TM, et al. (2007) Partial agonists activate PPARgamma using a helix 12 independent mechanism. Structure 15: 1258-1271.
13. Pochetti G, Godio C, Mitro N, Caruso D, Galmozzi A, et al. (2007) Insights into the mechanism of partial agonism: crystal structures of the peroxisome proliferator-activated receptor gamma ligand-binding domain in the complex with two enantiomeric ligands. J Biol Chem 282: 17314-17324.
14. Lu I-L, Huang C-F, Peng Y-H, Lin Y-T, Hsieh H-P, et al. (2006) Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities. J Med Chem 49: 2703-2712.
15. Gelman L, Feige JN, Desvergne B, (2007) Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes. Biochim Biophys Acta 1771: 1094-1107.
16. Choi JH, Banks AS, Estall JL, Kajimura S, Boström P, et al. (2010) Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466: 451-456.
17. Lewis SN, Bassaganya-Riera J, Bevan DR, (2010) Virtual Screening as a Technique for PPAR Modulator Discovery. PPAR Res 2010: 861238.
18. Markt P, Petersen RK, Flindt EN, Kristiansen K, Kirchmair J, et al. (2008) Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening. J Med Chem 51: 6303-6317.
19. Choi J, Park Y, Lee HS, Yang Y, Yoon S, (2010) 1,3-Diphenyl-1H-pyrazole derivatives as a new series of potent PPARγ partial agonists. Bioorg Med Chem 18: 8315-8323.
20. Vidović D, Busby SA, Griffin PR, Schürer SC, (2011) A Combined Ligand- and Structure-Based Virtual Screening Protocol Identifies Submicromolar PPARγPartial Agonists. ChemMedChem 6: 94-103.
21. Rau O, Wurglics M, Dingermann T, Abdel-Tawab M, Schubert-Zsilavecz M, (2006) Screening of herbal extracts for activation of the human peroxisome proliferator-activated receptor. Pharmazie 61: 952-956.
22. Salam NK, Huang TH-W, Kota BP, Kim MS, Li Y, et al. (2008) Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study. Chem Biol Drug Des 71: 57-70.
23. Huang TH-W, Kota BP, Razmovski V, Roufogalis BD, (2005) Herbal or natural medicines as modulators of peroxisome proliferator-activated receptors and related nuclear receptors for therapy of metabolic syndrome. Basic Clin Pharmacol Toxicol 96: 3-14.
24. Tanrikulu Y, Rau O, Schwarz O, Proschak E, Siems K, et al. (2009) Structure-based pharmacophore screening for natural-product-derived PPARgamma agonists. Chembiochem 10: 75-78.
25. Fakhrudin N, Ladurner A, Atanasov AG, Heiss EH, Baumgartner L, et al. (2010) Computer-aided discovery, validation, and mechanistic characterization of novel neolignan activators of peroxisome proliferator-activated receptor gamma. Mol Pharmacol 77: 559-566.
26. Petersen RK, Christensen KB, Assimopoulou AN, Fretté X, Papageorgiou VP, et al. (2010) Pharmacophore-driven identification of PPARγ agonists from natural sources. J Comput Aided Mol Des 25: 107-116.
27. Huang N, Shoichet BK, Irwin JJ, (2006) Benchmarking sets for molecular docking. J Med Chem 49: 6789-6801.
28. Irwin JJ, Shoichet BK, (2005) ZINC-a free database of commercially available compounds for virtual screening. J Chem Inf Model 45: 177-182.
29. Hopkins CR, O'neil SV, Laufersweiler MC, Wang Y, Pokross M, et al. (2006) Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis. Bioorg Med Chem Lett 16: 5659-5663.
30. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Res 28: 235-242.
31. Kleywegt GJ, Harris MR, Zou JY, Taylor TC, Wählby A, et al. (2004) The Uppsala Electron-Density Server. Acta Crystallogr D Biol Crystallogr 60: 2240-2249.
32. Guex N, Peitsch MC, (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18: 2714-2723.
33. Wolber G, Langer T, (2005) LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model 45: 160-169.
34. Wolber G, Dornhofer AA, Langer T, (2006) Efficient overlay of small organic molecules using 3D pharmacophores. J Comput Aided Mol Des 20: 773-788.
35. Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, et al. (2006) PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des 20: 647-671.
36. Lagorce D, Sperandio O, Galons H, Miteva MA, Villoutreix BO, (2008) FAF-Drugs2: free ADME/tox filtering tool to assist drug discovery and chemical biology projects. BMC Bioinformatics 9: 396.
37. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ, (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46: 3-26.
38. Zsoldos Z, Reid D, Simon A, Sadjad SB, Johnson AP, (2007) eHiTS: a new fast, exhaustive flexible ligand docking system. J Mol Graph Model 26: 198-212.
39. Mills N, (2006) ChemDraw Ultra 10.0. J Am Chem Soc 128: 13649-13650.
40. Schuster D, Wolber G, (2010) Identification of bioactive natural products by pharmacophore-based virtual screening. Curr Pharm Des 16: 1666-1681.
41. Duan J, Dixon SL, Lowrie JF, Sherman W, (2010) Analysis and comparison of 2D fingerprints: insights into database screening performance using eight fingerprint methods. J Mol Graph Model 29: 157-170.
42. Kelley LA, Gardner SP, Sutcliffe MJ, (1996) An automated approach for clustering an ensemble of NMR-derived protein structures into conformationally related subfamilies. Protein Eng 9: 1063-1065.
43. Ardévol A, Bladé C, Salvadó MJ, Arola L, (2000) Changes in lipolysis and hormone-sensitive lipase expression caused by procyanidins in 3T3-L1 adipocytes. Int J Obes Relat Metab Disord 24: 319-324.
44. Borenfreund E, Puerner JA, (1985) Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol Lett 24: 119-124.
45. Pinent M, Blay M, Bladé MC, Salvadó MJ, Arola L, et al. (2004) Grape seed-derived procyanidins have an antihyperglycemic effect in streptozotocin-induced diabetic rats and insulinomimetic activity in insulin-sensitive cell lines. Endocrinology 145: 4985-4990.
46. Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.